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*aDepartment Pharmaceutical Chemistry, Karnataka college of pharmacy, Bangalore, Karnataka, India 
bDepartment Pharmaceutical Chemistry, Manipal college of pharmaceutical sciences, Manipal, Karnataka, India  *Corresponding author email: deepthikini@gmail.com    A series of novel3-(substitutedbenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl) methanone P1-12 derivatives were synthesized. The chemical structures of the compounds were proved by means of their IR, 1H-NMR, mass spectroscopic data and elemental analyses. The results showed that most of the synthesized compounds exhibited significant anti-bacterial and anti-fungal activities. Among the synthesized compounds P2, P5, P8, and P9 exhibited most potent in vitro antimicrobial activity. On the basis of the microbial results, further  insight  into  the  structural  requirements  for  targeting  pyrazol-1-yl)(phenyl) methanone to develop potential new agents to combat treatment of pathogenic strains.  Keywords: pyrazole, Gram-positive, Gram-negative, fungal pathogenic strains     The clinical potential of microbial creation as therapeutic agents was first investigated by Pasteur and Joubert, who recorded their observation and speculation in 1877. The golden age of antibiotics began with the production of penicillin in 1941. The treatment of communicable diseases still leftovers an important and demanding problem because of amalgamation of factors including rising infectious diseases and the increasing number of multi-drug resistant microbial pathogens with particular relevance for bacteria and fungi (Tenover and McDonald 2005), (Roberts 2004). In this connection, we   have found that, the pyrazole structure has been known to possess a broad spectrum of biological activities. Severalresearch articles reported that pyrazole compounds posses many chemical, biological, medicinal and agricultural applications because of their adaptableand well recognized biological activities such as antimicrobial (Tanitame et al. 2004), (Bekhit and Abdel-Aziem 2004), (Tanitame et al. 2004), (Bekhit et al. 2008), antitumor (Park et al. 2005), antihistaminic (Yamashita et al. 2005) and antidepressant (Bailey et al. 1985).As documented in the literature, many pyrazole act as antimicrobial agents (Tanitame et al. 2004), (Liu et al. 2008), (Liu et al. 2008). Based on the above fact, we executed a series of compounds 3-(substitutedbenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone P1-12 containing pyrazole which could be effective for antimicrobial activity. 
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Materials and Methods Materials Synthetic starting material, reagents, and solvents were of analytical grade or of the highest quality commercially available. The chemicals were purchased from Aldrich Chemical Co., and Merck Chemical Co., Biotium, Inc., and were dried whenever necessary.The melting points were determined in open capillary tubes and are uncorrected. Infrared (IR) spectra were recorded with KBr pellets (ABB Bomem FT-IR spectrometer MB 104 ABB Limited, Bangaluru, India). Proton nuclear magnetic resonance (1H NMR) spectra (Bruker 400 NMR spectrometer, Mumbai, India) were recorded with tetramethylsilane as internal reference. Mass spectral data were recorded with a quadrupol mass spectrometer (Shimadzu GC MS QP 5000, Chennai, India), and microanalyses were performed using a vario EL V300 elemental analyzer (Analysensysteme GmbH, Chennai, India). The purity of the compounds was checked by TLC on pre-coated SiO2 gel (HF254, 200 mesh) aluminum plates (E. Merck). IR, 1H-NMR, mass spectral data, and elemental analyses were consistent with the assigned structure.  Methods Dissolve a 0.48g of the 5-methyl-1H-pyrazol-3-amine in a small quantity of absolute ethanol or methanol, and then excess quantity of benzaldehyde derivativeswas added to the mixture. The ratioused was of 3:1 means the mole quantity of benzaldehyde to each 1 mole of the pyrazole compound. The reaction mixture refluxed at 80oC for 12h and the reaction completion monitor by TLC. After the 1st step product separation and purification the solubility of the product is checked by using different solvents. Followed by the product is dissolved in etherand the exactly equal mole quantity of acetyl chloride is added carefully dropwise with shaking then refluxed at 80-100oC for 2-3h to afford the final product 3-(substituted benzylidene amino)-5-methyl-1H-pyrazol-1-yl) (phenyl) methanone P1-12  3-(2-fluorobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P1) The compound was obtained as a solid; Yield: 67%; m.p.174-176 °CIR cm-1: 3112 (Aromatic-CH), 2942 (Alkane-CH), 1660 (Hetero-C=N), 1731 (C=O), 1012 (C-F). 1H NMR (CDCl3) δ (ppm): 7.82 (s, 1H; Alkene-CH), 7.12-7.41 (m, 9H; Ar-H), 6.92 (s, 1H; Pyrazole-CH), 2.69 (s, 3H; -CH3). EI-MS m/z (M+2): 309 (calcd for C18H14FN3O; 307.32). Anal.calcd for C18H14FN3O; C, 70.35; H, 4.59; N, 13.67; Found C, 70.37; H, 4.53; N, 13.62.  3-(3-fluorobenzylideneaminho)-5-metyl-1H-pyrazol-1-yl)(phenyl)methanone (P2) The compound was obtained as a solid; Yield: 67%; m.p.182-183 °C IR cm-1: 3117 (Aromatic-CH), 2949 (Alkane-CH), 1653 (Hetero-C=N), 1729 (C=O), 1019 (C-F). 
1H NMR (CDCl3) δ (ppm): 7.72 (s, 1H; Alkene-CH), 7.22-7.47 (m, 9H; Ar-H), 6.96 (s, 1H; Pyrazole-CH), 2.28 (s, 3H; -CH3). EI-MS m/z (M+2): 309 (calcd for C18H14FN3O; 307.32). Anal.calcd for C18H14FN3O; C, 70.35; H, 4.59; N, 13.67; Found C, 70.34; H, 4.54; N, 13.66.  3-(4-fluorobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P3) The compound was obtained as a solid; Yield: 67%; m.p.162-164 °C IR cm-1: 3118 (Aromatic-CH), 2918 (Alkane-CH), 1641 (Hetero-C=N), 1726 (C=O), 1072 (C-F). 
1H NMR (CDCl3) δ (ppm): 7.75 (s, 1H; Alkene-CH), 7.31-7.42 (m, 9H; Ar-H), 6.71 (s, 1H; Pyrazole-CH), 2.52 (s, 3H; -CH3). EI-MS m/z (M+2): 309 (calcd for C18H14FN3O; 307.32).  Anal.calcd for C18H14FN3O; C, 70.35; H, 4.59; N, 13.67; Found C, 70.32; H, 4.52; N, 13.61.  
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3-(2-chlorobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P4) The compound was obtained as a  solid; Yield: 71%; m.p.165-167 °C IR cm-1: 3117 (Aromatic-CH), 2949 (Alkane-CH), 1664 (Hetero-C=N), 1736 (C=O), 644 (C-Cl). 
1H NMR (CDCl3) δ (ppm): 7.81 (s, 1H; Alkene-CH), 7.12-7.27 (m, 9H; Ar-H), 6.71 (s, 1H; Pyrazole-CH), 2.32 (s, 3H; -CH3). EI-MS m/z (M+2): 325 (calcd for C18H14ClN3O; 323.78).  Anal.calcd for C18H14ClN3O; C, 66.77; H, 4.36; N, 12.98; Found C, 66.72; H, 4.35; N, 12.96.  3-(3-chlorobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P5) The compound was obtained as a solid; Yield: 75%; m.p.175-176 °C IR cm-1: 3122 (Aromatic-CH), 2942 (Alkane-CH), 1667 (Hetero-C=N), 1732 (C=O), 651 (C-Cl). 
1H NMR (CDCl3) δ (ppm): 7.74 (s, 1H; Alkene-CH), 6.92-7.17 (m, 9H; Ar-H), 6.82 (s, 1H; Pyrazole-CH), 2.11 (s, 3H; -CH3). EI-MS m/z (M+2): 325 (calcd for C18H14ClN3O; 323.78).  Anal.calcd for C18H14ClN3O; C, 66.77; H, 4.36; N, 12.98; Found C, 66.73; H, 4.33; N, 12.92.  3-(4-chlorobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P6) The compound was obtained as a solid; Yield: 72%; m.p.185-187 °C IR cm-1: 3128 (Aromatic-CH), 2927 (Alkane-CH), 1641 (Hetero-C=N), 1720 (C=O), 744 (C-Cl). 
1H NMR (CDCl3) δ (ppm): 7.76(s, 1H; Alkene-CH), 6.96-7.19 (m, 9H; Ar-H), 6.85 (s, 1H; Pyrazole-CH), 4.44 (s, 1H; Alkene-CH), 2.17 (s, 3H; -CH3). EI-MS m/z (M+2): 325 (calcd for C18H14ClN3O; 323.78). Anal.calcd for C18H14ClN3O; C, 66.77; H, 4.36; N, 12.98; Found C, 66.72; H, 4.32; N, 12.94.  3-(2-bromobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P7) The compound was obtained as a solid; Yield: 68%; m.p.163-165 °C IR cm-1: 3129 (Aromatic-CH), 2931 (Alkane-CH), 1665 (Hetero-C=N), 1737 (C=O), 561 (C-Br). 
1H NMR (CDCl3) δ (ppm): 7.81 (s, 1H; Alkene-CH), 7.12-7.67 (m, 9H; Ar-H), 6.91 (s, 1H; Pyrazole-CH), 2.37 (s, 3H; -CH3). EI-MS m/z (M+2): 370 (calcd for C18H14BrN3O; 368.23).  Anal.calcd for C18H14ClN3O; C, 58.71; H, 3.83; N, 11.41; Found C, 58.73; H, 3.82; N, 11.44.  3-(3-bromobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P8) The compound was obtained as a solid; Yield: 75%; m.p.167-169 °C IR cm-1: 3132 (Aromatic-CH), 2937 (Alkane-CH), 1662 (Hetero-C=N), 1732 (C=O), 582 (C-Br). 
1H NMR (CDCl3) δ (ppm): 7.87 (s, 1H; Alkene-CH), 7.15-7.69 (m, 9H; Ar-H), 6.93 (s, 1H; Pyrazole-CH), 2.31 (s, 3H; -CH3). EI-MS m/z (M+2): 370 (calcd for C18H14BrN3O; 368.23). Anal.calcd for C18H14ClN3O; C, 58.71; H, 3.83; N, 11.41; Found C, 58.75; H, 3.83; N, 11.41.  3-(4-bromobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P9) The compound was obtained as a solid; Yield: 72%; m.p.166-168 °C IR cm-1: 3118 (Aromatic-CH), 2926 (Alkane-CH), 1641 (Hetero-C=N), 1697 (C=O), 592 (C-Br). 
1H NMR (CDCl3) δ (ppm): 7.85 (s, 1H; Alkene-CH), 7.11-7.64 (m, 9H; Ar-H), 6.46 (s, 1H; Pyrazole-CH), 2.35 (s, 3H; -CH3). EI-MS m/z (M+2): 370 (calcd for C18H14BrN3O; 368.23). Anal.calcd for C18H14ClN3O; C, 58.71; H, 3.83; N, 11.41; Found C, 58.73; H, 3.85; N, 11.47.  3-(2-nitrobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P10) The compound was obtained as a solid; Yield: 67%; m.p.157-159 °C  IR cm-1: 3131 (Aromatic-CH), 2937 (Alkane-CH), 2255 (Aliphatic-C=N), 1551 (N-O), 1652 (Hetero-C=N), 1712 (C=O). 
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1H NMR (CDCl3) δ (ppm): 7.82 (s, 1H; Alkene-CH), 7.19-7.76 (m, 9H; Ar-H), 6.94 (s, 1H; Pyrazole-CH), 2.17 (s, 3H; -CH3). EI-MS m/z (M+): 334 (calcd for C18H14N4O3; 334.33). Anal.calcd for C18H14ClN3O; C, 64.66; H, 4.22; N, 16.76; Found C, 64.61; H, 4.24; N, 16.72.  3-(3-nitrobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P11) The compound was obtained as a solid; Yield: 70%; m.p.141-143 °C IR cm-1: 3136 (Aromatic-CH), 1554 (N-O), 1656 (Hetero-C=N), 1719 (C=O). 
1H NMR (CDCl3) δ (ppm): 7.97 (s, 1H; Alkene-CH), 7.29-7.71 (m, 9H; Ar-H), 6.67 (s, 1H; Pyrazole-CH), 2.43 (s, 3H; -CH3). EI-MS m/z (M+): 334 (calcd for C18H14N4O3; 334.33). Anal.calcd for C18H14ClN3O; C, 64.66; H, 4.22; N, 16.76; Found C, 64.65; H, 4.24; N, 16.74.  3-(4-nitrobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone (P12) The compound was obtained as a solid; Yield: 76%; m.p.179-181 °C IR cm-1: 3118 (Aromatic-CH), 1519 (N-O), 1641 (Hetero-C=N), 1714 (C=O). 
1H NMR (CDCl3) δ (ppm): 7.92 (s, 1H; Alkene-CH), 7.15-7.74 (m, 9H; Ar-H), 6.69 (s, 1H; Pyrazole-CH), 2.47 (s, 3H; -CH3). EI-MS m/z (M+): 334 (calcd for C18H14N4O3; 334.33). Anal.calcd for C18H14ClN3O; C, 64.66; H, 4.22; N, 16.76; Found C, 64.63; H, 4.22; N, 16.71.  Antimicrobial Screening All the synthesized compounds were screened for antibacterial and antifungal activities by paper disc diffusion technique. The antibacterial activity of the compounds were evaluated against four gram positive bacteria (Staphylococcus aureus ATCC 9144, Staphylococcus epidermidis ATCC 155, MicrococcusluteusATCC 4698 and Bacillus cereus ATCC 11778) and three gram negative bacteria (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 2853 and Klebsiellapneumoniae ATCC 11298). The antifungal activities of the synthesized compounds were evaluated against two fungi (Aspergillusniger ATCC 9029 and Aspergillus fumigates ATCC 2091).  Paper Disc Diffusion Technique The sterilized (autoclaved at 120°C for 30 minutes) medium (40-50°C) was inoculated (1 mL/100 mL of medium) with the suspension (105cfu mL-1) of the microorganism (matched to McFarland barium sulphate standard) and poured into a petri dish to give a depth of 3-4 mm. The paper impregnated with the test compounds (µg mL-1 in dimethyl formamide) was placed on the solidified medium. The plates were pre-incubated for 1 h at room temperature and incubated at 37°C for 24 and 48 h for antibacterial and antifungal activities, respectively. Ciprofloxacin (Dr. Reddy’s Laboratories, Batch No: IC666E04, India) and Ketoconazole (Wuhan Shengmao Corporation, Batch No: SBML/403, China) were used as standard for antibacterial and antifungal activities, respectively.  Minimum Inhibitory Concentration (MIC) MIC of the compound was determined by agar streak dilution method. A stock solution of the synthesized compound (100 µg mL-1) in dimethylformamide was prepared and graded quantities of the test compounds were incorporated in specified quantity of molten sterile agar (nutrient agar for antibacterial activity and sabouraud dextrose agar medium for antifungal activity). A specified quantity of the medium (40-50°C) containing the compound was poured into a petri dish to give a depth of 3-4 mm and allowed to solidify. Suspension of the microorganism were prepared to contain approximately105cfu mL-1 and applied to plates with 
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serially diluted compounds in dimethylformamide to be tested and incubated at 37°C for 24 h and 48 h for bacteria and fungi, respectively. The MIC was considered to be the lowest concentration of the test substance exhibiting no visible growth of bacteria or fungi on the plate.  Statistical Analysis Student’s t-test was used to determine a significant difference between the control.  Results and Discussion Antimicrobial screening results of novel 3-(substituted benzylidene amino)-5-methyl-1H-pyrazol-1-yl) (phenyl) methanoneP1-12 derivatives exhibited moderate to significant activity. Among these, compound P2, P5, P8,and P9 were found to possess significant antibacterial and antifungal activity when compared to standard drug Ciprofloxacin and Ketoconazole. Compounds P3, P4,P6, P11 and P12 displayed least antimicrobial activity whereas the remaining compounds P1, P7 and P10 showed moderate activity.                          Scheme 1. The formation of 3-(substituted benzylideneaminho)-5-metyl-1H-pyrazol-1-yl)(phenyl) methanone   The compounds  3-(3-fluorobenzylideneaminho)-5-metyl-1H-pyrazol-1-yl)(phenyl)methanone P2, 3-(3-chlorobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone P5, 3-(3-bromobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone P8 and 3-(4-bromobenzylideneamino)-5-methyl-1H-pyrazol-1-yl)(phenyl)methanone P9, were found to exhibit the highest antimicrobial activity against S. aureus (24, 24, 24 and 24 g mL-1), S. epidermidis (28, 24, 28 and 28 g mL-1), M.luteus (26, 23, 26 and 26g mL-1), B. cereus (22, 21, 22 
N
NH
NH2
H3C +
H O
R
N
HN N
H3C
N
N N
H3C
O R
R
1
P1-12
Code RP1     o-FP2     m-FP3     p-FP4     o-ClP5     m-ClP6     p-ClP7     o-BrP8    m-BrP9     p-BrP10  o-NO2P11  m- NO2P12  p- NO2
Kini and Mathew /Research in Pharmacy, 5: 31-41, 2015   
36  
and 22 g mL-1),  E. coli (27, 24, 27 and 27), P. aeruginosa (24, 22, 24 and 23 g mL-1), K. pneumoniae (26, 24, 26 and 26 g mL-1), A.niger(MIC: 22, 20, 22 and 21g mL-1) andA. fumigatus (MIC: 23, 21, 23 and 22g mL-1) respectively. The MIC range of the synthesized compounds was 9.1-14.5 g mL-1 and compounds were active against all the tested microorganisms with a range of MIC values for S. aureus (9.1-11.7 g mL-1), S. epidermidis (9.1-13.1 g mL-1), M. luteus (9.2-11.6 g mL-1), B. cereus (9.1-12.1 g mL-1),  E. coli (9.8-12.7 g mL-1), P. aeruginosa (9.3-14.5 g mL-1), K. pneumoniae (9.2-12.6 g mL-1), A. niger(MIC: 9.3-11.7 g mL-1) and A. fumigatus (MIC: 10.2-12.4 g mL-1). On the basis of biological data, improvement in biological activity was observed with electronic effects and positions (ortho,meta, para) of the substituents. Considering the influence of electronic effects on the biological activities, electron withdrawing groups were introduced at 3rd position on the 5-methyl-1H-pyrazol-1-yl)(phenyl)methanone ring. Different analogues with electron withdrawing groups were synthesized e.g. electron withdrawing fluorine, chlorine, bromine and nitro, ortho, meta and para positions on the benzylidene ring. The potent antimicrobial activity exhibited by the compounds may be due to the incorporation of electron withdrawing groups. It was observed that the electrons withdrawing ortho, meta and para substituted compounds showed increase in antimicrobial activity. The observed inhibition figures on the antimicrobial activity of the synthesized compounds were shown in Figure. 1 The values for the antimicrobial studies of the compounds (P1-12) and the standard are represented in Table 1, 2 and 3.  Table 1.In vitro antimicrobial activities of the synthesized compounds P1-12  Zone of Inhibition in mm (MIC 100μg/ml) Gram Positive Bacteria Compound S.a S.e M.l B.c P1  20(11.7) 21(13.1) 22(11.3) 20(10.2) P2  24(9.6) 28(9.2) 26(9.8) 22(9.6) P3  22(13.2) 22(11.6) 21(11.2) 21(12.1) P4  21(11.1) 22(10.4) 21(11.6) 20(11.7) P5  24(9.9) 24(10.1) 23(10.7) 20(10.5) P6  21(10.4) 21(14.4) 21(11.5) 21(11.4) P7  20(10.1) 20(10.1) 20(10.7) 21(10.6) P8  20(9.9) 21(11.2) 21(10.9) 20(11.1) P9  24(9.1) 28(9.7) 26(9.2) 22(9.4) P10  21(10.2) 20(10.3) 20(10.4) 21(10.2) 
P11  21(10.1) 21(14.3) 21(11.2) 21(11.1) 
P12  20(10.3) 20(10.2) 20(10.3) 21(10.7) Ciprofloxacin  25 29 27 23 DMF - - - -   S.a- Staphylococcus aureus, S.e- Staphylococcus epidermidis, M.l- Micrococcus luteus  B.c- Bacillus cereus    
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Table 2. In vitro antimicrobial activities of the synthesized compounds P1-12   
  E.c- Escherichia coli; P.a- Pseudomonas aeruginosa; K.p- Klebsiellapneumoniae   Table 3. In vitro antimicrobial activities of the synthesized compounds P1-12  Zone of Inhibition in mm (MIC 100μg/ml) Fungi  Code  A.n A.f P1 20(11.7) 19(11.3) P2 22(10.1) 23(10.2) P3 18(11.7) 20(11.1) P4 18(11.1) 19(10.6) P5 20(11.2) 21(12.1) P6 19(11.4) 20(12.4) P7 18(11.5) 19(12.3) P8 20(11.6) 20(10.4) P9 22(9.3) 23(10.7) 
P10 18(11.2) 19(12.4) 
P11 18(11.4) 19(11.5) 
P12 18(11.2) 19(10.2) 
Ketoconazole DMF 27 - 25 -     A.n- Aspergillusniger;  A.f- Aspergillusfumigatus  
Zone of Inhibition in mm (MIC 100μg/ml) Gram Negative Bacteria Compound E.c P.a K.p P1 21(11.7) 21(10.6) 21(12.6) P2 27(10.2) 24(9.3) 26(9.7) P3 21(10.4) 21(14.5) 22(11.7) P4 22(11.2) 21(10.4) 20(12.2) P5 24(12.1) 22(10.7) 24(10.7) P6 23(12.1) 21(11.5) 21(10.2) P7 20(12.7) 21(12.5) 21(11.8) P8 23(10.1) 21(10.4) 21(11.1) P9 27(10.1) 24(9.5) 26(9.3) P10 20(12.2) 21(12.3) 21(11.2) 
P11 21(10.1) 21(13.2) 22(11.2) 
P12 21(11.4) 21(10.1) 20(12.5) 
Ciprofloxacin 28 25 27 
DMF - - - 
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                                            Figure 1. Antimicrobial activity slides of synthesized compounds P1-12   
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Figure 2. IR spectra of compound P3  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. IR spectra of compound P6 
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Figure 4. IR spectra of compound P9 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. IR spectra of compound P12 
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